EdenRed

Recovery underway

14/09/26 -"We upgrade our recommendation on Edenred from Reduce to Add as we believe most of the regulatory constraints are behind. Our €35 TP rests on a reworked framework revenue and FCF reaccelerating in ..."

PDF page sample
Pages
54
Language
English
Published on
14/09/26
Download
You may also be interested by these reports :
14/09/26
From bad to worse, the sector has jumped from one regulatory headwind to another during the last couple of years. Now that Edenred is roughly 50% up ...
14/09/26
We keep a Buy on Pluxee as Brazilian PAT is priced in and, unlike Edenred, there is no antitrust file. However, we remain cautious on the turnaround, ...
14/09/26
We upgrade our recommendation on Edenred from Reduce to Add as we believe most of the regulatory constraints are behind. Our €35 TP rests on a ...
10/09/26
sino AG has published good results again for Q3 26 (April-June 2026), underpinned by strong trading activity and commercial gains on the back of a ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO